肿瘤细胞治疗研究
英文原题：Evolution of cell therapy for renal cell carcinoma.
过去十年间，肾细胞癌（RCC）的治疗取得了显著进展，从高剂量细胞因子治疗联合手术切除肿瘤，转变为靶向治疗、免疫治疗及联合治疗。
过去十年，肾细胞癌（RCC）的治疗取得了显著进展，从高剂量细胞因子治疗联合手术切除肿瘤，转向靶向治疗、免疫治疗和联合治疗。然而，治愈性治疗，尤其是针对晚期疾病，仍然罕见。细胞治疗作为一种“活体药物”，已在血液系统恶性肿瘤中实现高缓解率的治愈，并且已有大量研究努力推动其向实体瘤的转化。本文中，我们概述了针对RCC的细胞治疗，重点关注异基因造血干细胞移植、T细胞受体基因修饰T细胞、嵌合抗原受体（CAR）T细胞、CAR自然杀伤（NK）细胞、淋巴因子激活的杀伤（LAK）细胞、T细胞和树突状细胞疫苗。我们还纳入了使用其他近期方法的展望，例如CAR巨噬细胞、树突状细胞-细胞因子诱导的杀伤细胞和调节性CAR-T细胞，以阐明细胞治疗的临床前开发，并推动细胞治疗进入临床，从而实现RCC的治愈。
Treatment for renal cell carcinoma (RCC) has improved dramatically over the last decade, shifting from high-dose cytokine therapy in combination with surgical resection of tumors to targeted therapy, immunotherapy, and combination therapies. However, curative treatment, particularly for advanced-stage disease, remains rare. Cell therapy as a "living drug" has achieved hematological malignancy cures with a high response rate, and significant research efforts have been made to facilitate its translation to solid tumors. Herein, we overview the cellular therapies for RCC focusing on allogeneic hematopoietic stem cell transplantation, T cell receptor gene-modified T cells, chimeric antigen receptor (CAR) T cells, CAR natural killer (NK) cells, lymphokine-activated killer (LAK) cells, T cells, and dendritic cell vaccination. We have also included perspectives for using other recent approaches, such as CAR macrophages, dendritic cell-cytokine induced killer cells and regulatory CAR-T cells to shed light on preclinical development of cell therapy and advancing cell therapy into clinic to achieve cures for RCC.
MEMBER ACCOUNT
登录成功会直接打开下一页。
